Alzamend Neuro stock rises by 5% as Alzheimer’s vaccine trial commences 04-Apr-2023 By Jonathan Smith The U.S. biotech Alzamend Neuro has launched a phase 1/2a trial of a therapeutic vaccine for Alzheimer’s disease based on a patient’s immune dendritic cells.